Rapport Therapeutics, Inc. Common Stock
RAPPRapport Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. The company leverages neuroscience research to identify novel targets and develop innovative treatments aimed at improving patient outcomes in conditions such as depression, anxiety, and other mental health disorders.
Company News
Rapport Therapeutics announced a public offering of 9,615,385 shares of common stock at $26.00 per share, expecting to raise approximately $250 million. The offering is expected to close on September 11, 2025, with Goldman Sachs, Jefferies, TD Cowen, and Stifel acting as joint book-running managers.
Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.
Rapport Therapeutics announced that its Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and on track to report topline results in September 2025. The company also provided updates on the RAP-219 development program and its financial position.
Rapport Therapeutics, a clinical-stage biotechnology company, announced two encore poster presentations at the 2025 AAN Annual Meeting. The presentations will highlight the company's ongoing research and development of RAP-219, a clinical-stage AMPA receptor negative allosteric modulator, for the treatment of refractory focal epilepsy.
Rapport Therapeutics announced positive results from its Phase 1 trials for RAP-219, a potential treatment for central nervous system disorders. The data showed that RAP-219 achieved target receptor occupancy and was generally well-tolerated, supporting its ongoing Phase 2a trial in focal epilepsy.
